2024 Global Life Sciences Summit

Highlights

The summit featured a variety of sessions and panels that covered the most relevant and urgent topics in the life sciences industry, such as:

The impact of AI on revolutionizing healthcare and life sciences.

Industry perspective on Tax Pillar Two and its implications for the life sciences sector.

M & A, deal execution trends, integration & separation, FTC Antitrust update, Biotechnology innovation hubs, and Biotechnology industry insights in China.

Health Equity, Impact of the new EU Pharma Review, AI Governance: Building frameworks for life sciences, and Navigating CSRD reporting in life sciences.

Unlocking life sciences potential with Generative AI, Computational modelling and simulation in Life Sciences: In Silico regulatory evidence and Gen AI potential, The role of data, analytics and AI in consumer healthcare.

The future of robotic surgery, Innovation in patient safety & quality in MedTech and China MedTech Outlook.

Patient leakage in precision medicine, how do we close the gaps?

The future and growth of Mental Health therapy.

The KPMG Global Life Sciences Summit 2024 was a successful and insightful event that showcased the diversity, dynamism, and excellence of the life sciences industry. The summit provided a platform for dialogue, collaboration, and learning among the leaders and experts of the industry, and highlighted the key challenges, opportunities, and innovations that are shaping the future of healthcare and life sciences. The summit also demonstrated the commitment and responsibility of the industry to address the needs and expectations of patients, regulators, and stakeholders, and to contribute to the global goals of health, well-being, and sustainability.

Agenda

Day 1: Tuesday, March 12, 2024
Masters of Ceremony:
Time	Session	Guest Speaker(s)	KPMG Host
10:00 am – 10:55 am	Session 1: Industry outlook
	1A: Welcome Remarks	Paul J. Knopp, Chair and CEO at KPMG US
	1B: Revolutionizing healthcare and life sciences: The impact of AI	Anna van Poucke, Global Head of Healthcare at KPMG International
	1C: Industry perspective on Tax Pillar Two	Jerome Mychalowych, Senior Vice President Global Tax, Pfizer	Joe Jasinski, Partner, Tax, KPMG US
	1D: Tax Pillar Two: Progress and challenges	Alyson Lawrence, Vice President, Global Taxation at Johnson & Johnson	Christine Kachinsky, National Sectors Leader - Tax, U.S. Life Sciences
	1E: Tax Pillar Two: Innovation in Global Tax Function	Dr. Tobias Kuck, Vice President, International Tax, Bayer	Marko Gruendig, Principal, Tax, BTS Strategic Corporate, KPMG US
11: 00 am – 11:55 am	Session 2: Deals & Strategy
	2A: Deal Execution Trends, Integration & Separation	Joanna Tuplin, VP Global Corporate Development at GSK	Tony Doyle Partner, Deal Advisory, UK Life Sciences Deal Execution Mark Harper, Partner - Deal Advisory, KPMG UK
	2B: FTC Antitrust Update	Arman Oruc, Partner & Co-Chair, Anti-Trust, Goodwin	Jeff Stoll, PhD, Partner, National Leader Life Sciences, Strategy Consulting, KPMG US
	2C: Life Science and Biotechnology innovation hubs: country attractiveness and government incentives	Gregory Rall, Deputy Head, Investment Promotion (Innovation & Technology), EU, UK & Nordics at Invest Hong Kong	Reza Ghafoorzadeh Nobar, Partner, Global Strategy Group, Life Science and Consumer Health Care, KPMG France
	2D: BioTech industry insights in China	Junpu XU, CEO, ACCB Bio Tech	Frank Mei, Head of Enterprise Risk Services KPMG Asia Pacific & China
12:00 pm – 12:55 pm	Session 3: Purpose & Impact
	3A: Health Equity	Kristin Schneeman, Senior Director at FasterCures, a Center of the Milken Institute	Fiona Thomas, Chief Medical Officer, KPMG UK
	3B: Impact of the new EU Pharma Review on the industry	Alan Morrison, Vice President International Regulatory Affairs at MSD	Anusha Foy, Partner KPMG, Head of Life Science Regulatory Solutions Practice, KPMG, UK
	3C: AI Governance: Building frameworks for life sciences	Stef Schutte, , Executive Vice President, Head of Regulatory Affairs, Astellas	Anusha Foy, Partner KPMG, Head of Life Science Regulatory Solutions Practice, KPMG, UK
	3D: Navigating CSRD reporting in life sciences	Sarah Dyson, Head of Corporate Responsibility at GSK	Nasrin Moola, Director, CLR ESG Assurance, KPMG UK Michael Wagemans, Partner, Head of Sustainability, Advisory, KPMG Belgium

Day 2: Wednesday, March 13, 2024
Masters of Ceremony:
Time	Session		Speaker(s)	KPMG Host
10:00 am – 10:55 am	Session 4: Technology & Innovation
	4A: Unlocking life sciences potential with Generative AI		Lana Feng, PhD, Co-founder and CEO, Huma.AI	Joseph Zaccaria, Managing Director, Deal Advisory & Strategy, HCLS, KPMG US
	4B: Computational modelling and simulation in Life Sciences: In Silico regulatory evidence and Gen AI potential		Professor Alejandro Frangi, PhD, Director, Christabel Pankhurst Institute Professor Michael Kipping, PhD Director, Medical Technologies EMEAA, Element Sheena Macpherson, CEO, adsilico	Anusha Foy, Partner KPMG, Head of Life Science Regulatory Solutions Practice, KPMG, UK
	4C: The role of data, analytics and AI in consumer healthcare		Gaurav Shah, Global Head of Data, Analytics & AI, Consumer Healthcare, Sanofi	Alison Little, Principal, Advisory, KPMG US
11:00 am – 11:55 am	Session 5: MedTech
	5A: The Future of robotic surgery		Riddhit Mitra, Senior Director of Product Management Robotics, Smith & Nephew, US	Jenny Harte, Partner, Life Sciences KPMG, UK
	5B: Innovation in patient safety & quality		Steve C de Baca, Chief Patient Safety and Quality Officer, Philips	Rajesh Misra, Principal, Life Sciences Operations Advisory, KPMG US
	5C: Patient safety & quality in MedTech		Peter Shearstone, Vice President, Global Quality and Regulatory at Thermo Fisher Scientific	Rajesh Misra, Principal, Life Sciences Operations Advisory, KPMG US
	5D: China MedTech Outlook		Ying Dai, Vice President & Chief Digital Officer, Johnson & Johnson MedTech	Frank Mei, Head of Enterprise Risk Services KPMG Asia Pacific & China
12:00 pm – 12:55 pm	Session 6: Precision Medicine
	6A: Patient leakage in precision medicine: How do we close the gaps?	Bonnie Anderson, Co-founder, CEO & Chair, PinkDx, Inc. Gabriel Bien-Willner, Medical Director, MolDX; CMO, Palmetto GBA Terri Conneran, Lung Cancer Survivor, KRAS Kickers Dr. Ed Kim, Senior Vice President & Physician-in-Chief, City of Hope		Alasdair Milton, Principal, Healthcare and Life Sciences Strategy, KPMG US
	6B: The Future and growth of Mental health Therapy	Sahil Kirpekar, M.D, Chief Business Officer, atai Life Sciences Johan Luthman, Executive Vice President and Head of R & D, Lundbeck		Varun Renjen, Managing Director, Life Sciences, KPMG US
	6C: Closing Remarks	Kristin Pothier, Global Life Sciences Deal Advisory and Strategy Leader, KPMG US

Day 1: Tuesday, March 12, 2024
Masters of Ceremony:
Time	Session	Guest Speaker(s)	KPMG Host
10:00 am – 10:55 am	Session 1: Industry outlook
	1A: Welcome Remarks	Paul J. Knopp, Chair and CEO at KPMG US
	1B: Revolutionizing healthcare and life sciences: The impact of AI	Anna van Poucke, Global Head of Healthcare at KPMG International
	1C: Industry perspective on Tax Pillar Two	Jerome Mychalowych, Senior Vice President Global Tax, Pfizer	Joe Jasinski, Partner, Tax, KPMG US
	1D: Tax Pillar Two: Progress and challenges	Alyson Lawrence, Vice President, Global Taxation at Johnson & Johnson	Christine Kachinsky, National Sectors Leader - Tax, U.S. Life Sciences
	1E: Tax Pillar Two: Innovation in Global Tax Function	Dr. Tobias Kuck, Vice President, International Tax, Bayer	Marko Gruendig, Principal, Tax, BTS Strategic Corporate, KPMG US
11: 00 am – 11:55 am	Session 2: Deals & Strategy
	2A: Deal Execution Trends, Integration & Separation	Joanna Tuplin, VP Global Corporate Development at GSK	Tony Doyle Partner, Deal Advisory, UK Life Sciences Deal Execution Mark Harper, Partner - Deal Advisory, KPMG UK
	2B: FTC Antitrust Update	Arman Oruc, Partner & Co-Chair, Anti-Trust, Goodwin	Jeff Stoll, PhD, Partner, National Leader Life Sciences, Strategy Consulting, KPMG US
	2C: Life Science and Biotechnology innovation hubs: country attractiveness and government incentives	Gregory Rall, Deputy Head, Investment Promotion (Innovation & Technology), EU, UK & Nordics at Invest Hong Kong	Reza Ghafoorzadeh Nobar, Partner, Global Strategy Group, Life Science and Consumer Health Care, KPMG France
	2D: BioTech industry insights in China	Junpu XU, CEO, ACCB Bio Tech	Frank Mei, Head of Enterprise Risk Services KPMG Asia Pacific & China
12:00 pm – 12:55 pm	Session 3: Purpose & Impact
	3A: Health Equity	Kristin Schneeman, Senior Director at FasterCures, a Center of the Milken Institute	Fiona Thomas, Chief Medical Officer, KPMG UK
	3B: Impact of the new EU Pharma Review on the industry	Alan Morrison, Vice President International Regulatory Affairs at MSD	Anusha Foy, Partner KPMG, Head of Life Science Regulatory Solutions Practice, KPMG, UK
	3C: AI Governance: Building frameworks for life sciences	Stef Schutte, , Executive Vice President, Head of Regulatory Affairs, Astellas	Anusha Foy, Partner KPMG, Head of Life Science Regulatory Solutions Practice, KPMG, UK
	3D: Navigating CSRD reporting in life sciences	Sarah Dyson, Head of Corporate Responsibility at GSK	Nasrin Moola, Director, CLR ESG Assurance, KPMG UK Michael Wagemans, Partner, Head of Sustainability, Advisory, KPMG Belgium

Day 2: Wednesday, March 13, 2024
Masters of Ceremony:
Time	Session		Speaker(s)	KPMG Host
10:00 am – 10:55 am	Session 4: Technology & Innovation
	4A: Unlocking life sciences potential with Generative AI		Lana Feng, PhD, Co-founder and CEO, Huma.AI	Joseph Zaccaria, Managing Director, Deal Advisory & Strategy, HCLS, KPMG US
	4B: Computational modelling and simulation in Life Sciences: In Silico regulatory evidence and Gen AI potential		Professor Alejandro Frangi, PhD, Director, Christabel Pankhurst Institute Professor Michael Kipping, PhD Director, Medical Technologies EMEAA, Element Sheena Macpherson, CEO, adsilico	Anusha Foy, Partner KPMG, Head of Life Science Regulatory Solutions Practice, KPMG, UK
	4C: The role of data, analytics and AI in consumer healthcare		Gaurav Shah, Global Head of Data, Analytics & AI, Consumer Healthcare, Sanofi	Alison Little, Principal, Advisory, KPMG US
11:00 am – 11:55 am	Session 5: MedTech
	5A: The Future of robotic surgery		Riddhit Mitra, Senior Director of Product Management Robotics, Smith & Nephew, US	Jenny Harte, Partner, Life Sciences KPMG, UK
	5B: Innovation in patient safety & quality		Steve C de Baca, Chief Patient Safety and Quality Officer, Philips	Rajesh Misra, Principal, Life Sciences Operations Advisory, KPMG US
	5C: Patient safety & quality in MedTech		Peter Shearstone, Vice President, Global Quality and Regulatory at Thermo Fisher Scientific	Rajesh Misra, Principal, Life Sciences Operations Advisory, KPMG US
	5D: China MedTech Outlook		Ying Dai, Vice President & Chief Digital Officer, Johnson & Johnson MedTech	Frank Mei, Head of Enterprise Risk Services KPMG Asia Pacific & China
12:00 pm – 12:55 pm	Session 6: Precision Medicine
	6A: Patient leakage in precision medicine: How do we close the gaps?	Bonnie Anderson, Co-founder, CEO & Chair, PinkDx, Inc. Gabriel Bien-Willner, Medical Director, MolDX; CMO, Palmetto GBA Terri Conneran, Lung Cancer Survivor, KRAS Kickers Dr. Ed Kim, Senior Vice President & Physician-in-Chief, City of Hope		Alasdair Milton, Principal, Healthcare and Life Sciences Strategy, KPMG US
	6B: The Future and growth of Mental health Therapy	Sahil Kirpekar, M.D, Chief Business Officer, atai Life Sciences Johan Luthman, Executive Vice President and Head of R & D, Lundbeck		Varun Renjen, Managing Director, Life Sciences, KPMG US
	6C: Closing Remarks	Kristin Pothier, Global Life Sciences Deal Advisory and Strategy Leader, KPMG US

Insights

Services

Industries

How We Work

Careers & Culture

Relevant Results

Sorry, there are no results matching your search.

2024 Global Life Sciences Summit